Ampullary Cancer Ampullary Cancer [Member] Ampullary Cancer Grants in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Olumiant® Olumiant [Member] Olumiant [Member] Plan assets, target allocation Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Expected future employer contributions, next fiscal year Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Change in benefit obligation: Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Contingencies Commitments and Contingencies Disclosure [Text Block] Change in plan assets: Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Deferred income tax liabilities assumed Deferred income taxes Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Lebrikizumab Lebrikizumab [Member] Lebrikizumab [Member] Neuroscience Neuroscience [Member] Revenue to unaffiliated customers, Neuroscience LIFO Inventory Amount LIFO Inventory Amount Cash and cash equivalents at beginning of year (includes $677.5 (2019) and $324.4 (2018) of discontinued operations) Cash and Cash Equivalents at End of Year (includes $677.5 (2018) of discontinued operations) Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 7.125% notes due 2025 7.125% Notes Due 2025 [Member] 7.125% Notes Due 2025 Selpercatinib (LOXO-292) Selpercatinib (LOXO-292) [Member] Selpercatinib (LOXO-292) [Member] China CHINA Schedule of Changes in Accumulated Postemployment Benefit Obligations Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block] Other Diabetes Other Diabetes [Member] Other Diabetes Dermira Dermira, Inc. [Member] Dermira, Inc. [Member] Revenue, information used to determine revenue recognized, change in accounting estimate, percent Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Statistical Measurement [Domain] Statistical Measurement [Domain] Liabilities and Equity Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Loxo Oncology, Inc. Loxo Oncology, Inc. [Member] Loxo Oncology, Inc. [Member] Security Exchange Name Security Exchange Name Short-term investments: Debt Securities, Available-for-sale, Sale [Abstract] Fair value of plan assets at beginning of year Fair value of plan assets at end of year Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt Long-lived Assets by Geographic Areas Long-lived Assets by Geographic Areas [Table Text Block] Retirement of treasury shares Treasury Stock, Retired, Cost Method, Amount Total current liabilities Liabilities, Current Curtailment (gain) loss Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment Marketable equity securities Marketable Securities [Member] Marketable Securities [Member] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Performance Shares Performance Shares [Member] Claims settled and dismissed, limited initial market entry, supply term Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Assets Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Proceeds from sales of noncurrent investments Proceeds from Sale and Maturity of Other Investments Stock-based compensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Operating cash flows from operating leases Operating Lease, Payments Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] 2023 Long-Term Debt, Maturity, Year Three Statement [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Intangibles Deferred Tax Liabilities, Goodwill and Intangible Assets Weighted average useful life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Year 1 Lessee, Operating Lease, Liability, to be Paid, Year One Purchase of treasury shares (in shares) Treasury Stock, Shares, Acquired Year 4 Lessee, Operating Lease, Liability, to be Paid, Year Four Total compensation cost not yet recognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount State Current State and Local Tax Expense (Benefit) Tax credit carryforward Tax Credit Carryforward, Amount Earnings from continuing operations - diluted (in usd per share) Income (Loss) from Continuing Operations, Per Diluted Share Designated Unusable Designated Unusable [Member] Those operating loss/tax credit carryforwards/carrybacks included that have been designated to be unusable and therefore, is fully reserved. Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) Junshi Biosciences [Member] Junshi Biosciences Building Building [Member] 2023 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Fair value adjustment on hedged long-term notes Long-term Debt, Fair Value Adjustment Fair value adjustment to carrying value of long term debt to arrive at total fair value. Evox Therapeutics Ltd Evox Therapeutics [Member] Evox Therapeutics Other noncurrent liabilities Other Liabilities, Noncurrent Deferred tax assets (Note 14) Deferred Income Tax Assets, Net Employee Litigation Employee Litigation [Member] Employee Litigation [Member] Operating Activities [Axis] Operating Activities [Axis] Brazil BRAZIL AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Document Information [Table] Document Information [Table] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Unfunded commitments to invest in venture capital funds, anticipated payment period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Sigilon Therapeutics, Inc. Sigilon Therapeutics [Member] Sigilon Therapeutics [Member] Inventories (Note 6) Inventories Inventory, Net Net income from continuing operations Reclassifications from continuing operations (net of tax) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Concentration risk, percentage Concentration Risk, Percentage 6-10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Fair value of plan assets Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Bamlanivimab Bamlanivimab [Member] Bamlanivimab Deferred federal income tax benefit, effect of 2017 Tax Act Deferred Federal Income Tax Expense (Benefit), Effect Of Tax Cuts And Jobs Act Deferred Federal Income Tax Expense (Benefit), Effect Of Tax Cuts And Jobs Act Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Statement [Line Items] Statement [Line Items] Innovent Biologics, Inc. (Innovent) Innovent Biologics, Inc. [Member] Innovent Biologics, Inc. Revenue, performance obligation, sales returns, percentage of net revenue (less than) Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue Class of Stock [Domain] Class of Stock [Domain] No Expiration No Expiration [Member] Those operating loss/tax credit carryforwards/carrybacks included that have no expiration. Tax Period [Axis] Tax Period [Axis] Debt instrument, term Debt Instrument, Term Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Statement [Table] Statement [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Compensation and benefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Interest cost Defined Benefit Plan, Interest Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Equity-like funds Equity Funds [Member] Byetta Byetta [Member] Byetta Ireland IRELAND Other foreign countries Other foreign countries Other Foreign Countries [Member] Other Foreign Countries [Member] Earnings of foreign subsidiaries Deferred Tax Liabilities, Undistributed Foreign Earnings Milestones payments Collaborative Arrangement, Rights and Obligations, Rights (Obligations) Collaborative Arrangement, Rights And Obligations, Rights (Obligations) Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax AC Immune SA AC Immune SA [Member] AC Immune SA [Member] Basaglar® Basaglar [Member] Basaglar [Member] Entity Small Business Entity Small Business Initial public offering (in shares) Sale of Stock, Number of Shares Issued in Transaction Borrowings Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Contingent value right, monthly reduction Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs Prepaid expenses and other Prepaid Expense, Current Share Repurchase Program [Domain] Share Repurchase Program [Domain] Amortization of net actuarial loss included in net income Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax Amendment Flag Amendment Flag Shares used in calculation of earnings per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Accruals for the payment of interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Shares held in employee trust (in shares) Common Stock, Shares Held in Employee Trust, Shares Financial Instruments [Domain] Financial Instruments [Domain] 2017 Tax Act, deferred taxes related to GILTI Tax Cuts and Jobs Act of 2017, Deferred Tax Asset, Global Intangible Low-Taxed Income Provision Tax Cuts and Jobs Act of 2017, Deferred Tax Asset, Global Intangible Low-Taxed Income Provision Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Fair Value, by Balance Sheet Grouping Fair Value, by Balance Sheet Grouping [Table Text Block] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Revenue, performance obligation, payment terms, financing component, period between transfer of control and payment receipt (or less) Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt Derivatives Derivatives, Policy [Policy Text Block] Shares issued in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Taltz® Taltz [Member] Taltz [Member] Long-term income taxes payable (Note 14) Accrued Income Taxes, Noncurrent Commitments and Contingencies Commitments and Contingencies, Policy [Policy Text Block] 3.00% notes due 2022 3.0% Notes Due 2022 [Member] 3.0% Notes Due 2022 Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] 3.95% notes due 2049 3.95% Notes Due 2049 [Member] 3.95% Notes Due 2049 [Member] Accounts receivable, allowances Accounts Receivable, Allowance for Credit Loss, Current Verzenio® Verzenio [Member] Verzenio [Member] 4.15% notes due 2059 4.15% Notes Due 2059 [Member] 4.15% Notes Due 2059 [Member] Effective Portion of Cash Flow Hedges Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Year 2 Lessee, Operating Lease, Liability, to be Paid, Year Two Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] State and Local Jurisdiction State and Local Jurisdiction [Member] Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Marketing, selling, and administrative Selling, General and Administrative Expense Other securities Other Debt Obligations [Member] Foreign currency exchange contracts Foreign Exchange Contract [Member] Schedule of Impact of Leases to Consolidated Condensed Financial Statements Lease, Cost [Table Text Block] Year 3 Lessee, Operating Lease, Liability, to be Paid, Year Three Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure 5.95% notes due 2037 5.95% Notes Due 2037 [Member] 5.95% Notes Due 2037 Total assets Assets Schedule of Net Funded Status Schedule of Net Funded Status [Table Text Block] Pancreatitis Pancreatitis [Member] Pancreatitis Discontinued operations cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations ImmuNext, Inc. ImmuNext, Inc. [Member] ImmuNext, Inc. [Member] Amortization of prior service (benefit) cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Defined Benefit Plan, Expected Future Benefit Payment [Abstract] Defined Benefit Plan, Expected Future Benefit Payment [Abstract] Gain on sale of antibiotic business in China (Note 3) Gain related to disposition Gain on sale of antibiotic business in China (Note 3) Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Subsequent Event Type [Axis] Subsequent Event Type [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Other assets and liabilities - net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets and Liabilities, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets and Liabilities, Net Concentration Risk, Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Acquisitions and Divestiture Mergers, Acquisitions and Dispositions Disclosures [Text Block] Other Oncology Other Oncology [Member] Other Oncology [Member] 0.625% Euro denominated notes due 2031 .625% Euro-deonominated Notes Due 2031 [Member] .625% Euro-deonominated Notes Due 2031 [Member] Other Other intangibles Other Intangible Assets [Member] Hedged Fixed Rate Debt Hedged Fixed Rate Debt [Member] Hedged Fixed-Rate Debt [Member] Accounts receivable derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Carryforward Carryforward [Member] Tax Carryforward [Member] Schedule of Amounts Recognized in Other Comprehensive Income (Loss) Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Total accumulated benefit obligation for our defined benefit pension plans Defined Benefit Plan, Accumulated Benefit Obligation Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Asahi Kasei Pharma Corporation Asahi Kasei Pharma Corporation [Member] Asahi Kasei Pharma Corporation Fair value of securities in an unrealized loss position Debt Securities, Available-for-sale, Unrealized Loss Position Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Income tax (benefit) expense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Inventories—(increase) decrease Increase (Decrease) in Inventories Tax Years 2013 to 2015 Tax Years 2013 To 2015 [Member] Tax Years 2013 To 2015 [Member] Fair value hedges: Fair Value Hedge [Abstract] Fair Value Hedge [Abstract] Additional Paid-in Capital Additional Paid-in Capital [Member] Schedule of Other Nonoperating Income (Expense) Schedule of Other Nonoperating Income (Expense) [Table Text Block] Total (approximates replacement cost) Inventory, Gross Other non-cash operating activities, net Other Operating Activities, Cash Flow Statement Purchases of intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Japan JAPAN Alimta® Alimta [Member] Alimta [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Issued Other noncurrent assets Other Assets, Miscellaneous, Noncurrent Earnings from continuing operations - basic (in usd per share) Income (Loss) from Continuing Operations, Per Basic Share Other receivables Other Receivables Deferred tax assets: Deferred Tax Assets, Net [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] 3-5 Years Tax Cut And Jobs Act, Toll Tax, To Be Paid, After Three Through Five Years Tax Cut And Jobs Act, Toll Tax, To Be Paid, After Three Through Five Years Income before income taxes Total before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest IPO IPO [Member] Cash paid for acquisitions, net of cash acquired (Note 3) Payments to Acquire Businesses, Net of Cash Acquired Authorized (in shares) Common Stock, Shares Authorized Total debt Debt, Long-term and Short-term, Combined Amount Property and equipment, gross Property, Plant and Equipment, Gross Employee Benefit Trust Trust for Benefit of Employees [Member] Federal Deferred Federal Income Tax Expense (Benefit) 2022 Defined Benefit Plan, Expected Future Benefit Payment, Year Two November 2019 Euro-denominated Notes November 2019 Euro-denominated Notes [Member] November 2019 Euro-denominated Notes 7 1/8% Notes due 2025 7 1/8% Notes Due June 1, 2025 [Member] 7 1/8% Notes Due June 1, 2025 [Member] Funded status Defined Benefit Plan, Funded (Unfunded) Status of Plan Expiration 5 to 20 Years Expiration 5 to 20 Years [Member] Expiration 5 to 20 Years [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition Income Statement [Abstract] Income Statement [Abstract] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Schedule of Additional Borrowings Disclosures Schedule of Additional Borrowings Disclosures [Table Text Block] Schedule of Additional Borrowings Disclosures [Table Text Block] Change in Accounting Estimate [Line Items] Change in Accounting Estimate [Line Items] Cash provided by operating activities, discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Deferred tax assets related to state net operating losses Deferred Tax Assets, Operating Loss Carryforwards, State and Local Schedule of Change in Accounting Estimate [Table] Schedule of Change in Accounting Estimate [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Immunology Immunology [Member] Immunology [Member] Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Product Liability Product Liability [Member] Product Liability Income Tax Authority [Domain] Income Tax Authority [Domain] Cash dividends declared Dividends Schedule of Assumptions Used Defined Benefit Plan, Assumptions [Table Text Block] Schedule of Changes in Fair Value of Plan Assets Schedule of Changes in Fair Value of Plan Assets [Table Text Block] 1.625% Euro denominated notes due 2026 1.625% Euro-denominated Notes Due 2026 [Member] 1.625% Euro-denominated Notes Due 2026 Scenario [Domain] Scenario [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Goodwill and Other Intangibles Goodwill and Intangible Assets Disclosure [Text Block] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Realized gross gains on sales Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Disposal group, not discontinued operation, payment to be received Disposal Group, Not Discontinued Operation, Payment To Be Received Disposal Group, Not Discontinued Operation, Payment To Be Received 0.15% Swiss Franc denominated notes due 2024 0.15% Swiss Franc-denominated Notes Due 2024 [Member] 0.15% Swiss Franc-denominated Notes Due 2024 Hedging Designation [Axis] Hedging Designation [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] 2026-2030 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Operating Lease, Liability, Statement of Financial Position [Extensible List] Operating Lease, Liability, Statement of Financial Position [Extensible List] Equity securities Equity Securities, FV-NI Entity [Domain] Entity [Domain] Designated as Hedging Instrument Designated as Hedging Instrument [Member] 2.125% Euro denominated notes due 2030 2.125% Euro-denominated Notes Due 2030 [Member] 2.125% Euro-denominated Notes Due 2030 Schedule of Other Operating Cost and Expense, by Component Restructuring and Related Costs [Table Text Block] Current federal tax expense, effect of 2017 Tax Act Current Federal Tax Expense (Benefit), Effect Of Tax Cuts And Jobs Act Current Federal Tax Expense (Benefit), Effect Of Tax Cuts And Jobs Act Available-for-sale Securities Debt Securities, Available-for-sale [Table Text Block] 2.35% notes due 2022 2.35% Notes Due 2022 [Member] 2.35% Notes Due 2022 Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al. Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al. [Member] Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al. Estimated useful life Property, Plant and Equipment, Useful Life Proceeds from sales Proceeds from Sale of Equity and Available for Sale Securities Proceeds from Sale of Equity and Available for Sale Securities Change in effective portion of cash flow hedges Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax 0.42% Japanese Yen denominated notes due 2029 .42% Yen-denominated Notes Due 2029 [Member] .42% Yen-denominated Notes Due 2029 [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Weiler v. Takeda Canada Inc. et al. Weiler V. Takeda Canada Inc. Et Al. [Member] Weiler V. Takeda Canada Inc. Et Al. Collaborative arrangement, rights and obligations percent Collaborative Arrangement, Rights and Obligations Percent Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes. 1-3 Years Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years Deferred tax assets Deferred tax assets, net Deferred Tax Assets, Net Total Debt Securities, Available-for-sale Trulicity® Trulicity [Member] [Member] Trulicity [Member] [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Purchases of in-process research and development Purchased in-process research and development The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS). Diabetes Diabetes [Member] Diabetes Weighted average interest rate Short-term Debt, Weighted Average Interest Rate, at Point in Time Various State Domiciles Various State Domiciles [Member] Various State Domiciles Realized gross losses on sales Available for sale Securities and Equity Securities, FV-NI, Realized Loss Available for sale Securities and Equity Securities, FV-NI, Realized Loss Financial Instruments Fair Value Disclosures [Text Block] Avidity Biosciences, Inc. Avidity Biosciences, Inc. [Member] Avidity Biosciences, Inc. [Member] Accounts Receivable Accounts Receivable [Member] Remaining amortization period Finite-Lived Intangible Assets, Remaining Amortization Period Forward-starting interest rate swaps Interest Rate Swap [Member] Customer [Domain] Customer [Domain] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Entity Registrant Name Entity Registrant Name Subsequent Event Type [Domain] Subsequent Event Type [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Eli Lilly and Company Eli Lilly And Company [Member] Eli Lilly And Company [Member] Epp v. Takeda Canada Inc. et al. Epp V. Takeda Canada Inc. Et Al. [Member] Epp V. Takeda Canada Inc. Et Al. AurKa Pharma Inc. Aurka Pharma [Member] Aurka Pharma [Member] Tanezumab Tanezumab [Member] Tanezumab [Member] Defined benefit obligation, period increase Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease) Foreign currency exchange rate changes and other Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax Non-deductible acquired IPR&D Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Unrealized gross losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Revenue, performance obligation, payment terms, days from date of shipment, maximum Revenue from Contract, Payment Term, Maximum Revenue from Contract, Payment Term, Maximum Sale of Stock [Axis] Sale of Stock [Axis] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code 3.875% notes due 2039 3.875% Notes Due 2039 [Member] Senior Notes Due 2039 [Member] Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Effective Portion of Cash Flow Hedges Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member] Domestic and Puerto Rican companies contribution Domestic and Puerto Rican Contribution to Income before Income Taxes Percent contribution of most significant (domestic, including Puerto Rico) areas that contributed to the consolidated income (loss) before income taxes. Goodwill (Note 8) Goodwill Goodwill Goodwill Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 0.625% Notes due 2031 .625% Notes due 2031 [Member] .625% Notes due 2031 [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Tax loss carryforwards and carrybacks Deferred Tax Assets, Operating Loss Carryforwards Revenue, performance obligation, payment terms, days from date of shipment, minimum Revenue from Contract, Payment Term, Minimum Revenue from Contract, Payment Term Income taxes payable—increase (decrease) Increase (Decrease) in Income Taxes Payable Cash dividend declared per share (in usd per share) Common Stock, Dividends, Per Share, Declared Debt instrument, face amount Debt Instrument, Face Amount International operations, including Puerto Rico Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount Expected future employer discretionary contributions, next fiscal year Defined Benefit Plan, Expected Future Employer Discretionary Contributions, Next Fiscal Year Defined Benefit Plan, Expected Future Employer Discretionary Contributions, Next Fiscal Year Increase to LIFO cost Inventory, LIFO Reserve Equity [Abstract] Equity [Abstract] Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Gain (Loss) on Investments Gain (Loss) on Securities [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Derivative, Name [Domain] Derivative Contract [Domain] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Revenue, performance obligation, sales returns, product expiration date Revenue, Performance Obligation, Sales Returns, Product Expiration Date Revenue, Performance Obligation, Sales Returns, Product Expiration Date Sitryx Therapeutics Limited Sitryx Therapeutics Limited [Member] Sitryx Therapeutics Limited [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax ARMO BioSciences, Inc. (ARMO) ARMO Biosciences, Inc. [Member] ARMO Biosciences, Inc. [Member] Cost Portion at Other than Fair Value Measurement [Member] Net Cash Used for Financing Activities Net Cash Provided by (Used in) Financing Activities Repayments of long-term debt Repayments of long-term debt Repayments of Long-term Debt Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Maturity Date, 2023 Maturity Date, 2023 [Member] Maturity Date, 2023 Outside of China Non-CHINA [Member] Non-CHINA Anima Biotech Inc. Anima Biotech [Member] Anima Biotech [Member] Beginning balance Ending balance Unrecognized Tax Benefits Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Common stock—no par value
 Authorized shares: 3,200,000
 Issued shares: 957,077 (2020) and 958,056 (2019) Common Stock, Value, Issued Investments (Note 7) Noncurrent investments Long-term Investments 2024 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Finite-lived intangible assets: Finite-Lived Intangible Assets [Line Items] Document Fiscal Year Focus Document Fiscal Year Focus Equity method investments Other Long-term Investments 2022 Finite-Lived Intangible Asset, Expected Amortization, Year Two Legacy Antibiotic Medicines and a Manufacturing Facility in Suzhou, China Legacy Antibiotic Medicines And A Manufacturing Facility In Suzhou, China [Member] Legacy Antibiotic Medicines And A Manufacturing Facility In Suzhou, China [Member] Benefit obligation at beginning of year Benefit obligation at end of year Defined Benefit Plan, Benefit Obligation Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Entity Current Reporting Status Entity Current Reporting Status Sale of stock, price per share (in usd per share) Sale of Stock, Price Per Share Acquisition of common stock in exchange offer Stock Acquired During Period, Value, Exchange Offer Stock Acquired During Period, Value, Exchange Offer Short-term borrowings and current maturities of long-term debt (Note 11) Less current portion Debt, Current 3.7% notes due 2045 3.7% Notes Due 2045 [Member] 3.7% Notes Due 2045 Currency Swap Currency Swap [Member] Earnings Per Share (EPS) Earnings Per Share, Policy [Policy Text Block] Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 0.97% Japanese Yen denominated notes due 2049 .97% Yen-deonominated Notes Due 2049 [Member] .97% Yen-deonominated Notes Due 2049 Elanco Elanco Animal Health Incorporated [Member] Elanco Animal Health Incorporated [Member] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Business acquisition, share price (in dollars per share) Business Acquisition, Share Price Collaborations and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents (Note 7) Cash and Cash Equivalents, at Carrying Value Total Tax Cut And Jobs Act, Toll Tax, To Be Paid Tax Cut And Jobs Act, Toll Tax, To Be Paid Percentage of stock sold Sale Of Stock, Percentage Of Stock Sold Sale Of Stock, Percentage Of Stock Sold Fair value of securities in an unrealized gain position Debt Securities, Available-for-sale, Unrealized Gain Position Debt Securities, Available-for-sale, Unrealized Gain Position Schedule of Additional Stock-Based Compensation Disclosures Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block] Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block] Buy GBP Sell USD Buy GBP Sell USD [Member] Buy GBP Sell USD Operating lease, liability Total Operating Lease, Liability Sales returns, rebates, and discounts Sales Returns and Allowances [Member] Deferred tax liabilities Deferred Tax Liabilities, Net Expiration within 5 years Expiration within 5 years [Member] Expiration within 5 years [Member] Long-term debt (Note 11) Long-term debt Long-term Debt, Excluding Current Maturities Share Repurchase Program [Axis] Share Repurchase Program [Axis] Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument [Line Items] Total Eli Lilly and Company shareholders' equity Stockholders' Equity Attributable to Parent Consideration transferred Business Combination, Consideration Transferred Raw materials and supplies Inventory, Raw Materials, Gross Entity Address, City or Town Entity Address, City or Town Long-term notes Notes Payable Employee compensation Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Acquired IPR&D charges Payments to Acquire Intangible Assets Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Damages awarded, value Loss Contingency, Damages Awarded, Value U.S. and Puerto Rico UNITED STATES And PUERTO RICO [Member] UNITED STATES And PUERTO RICO [Member] Year 5 Lessee, Operating Lease, Liability, to be Paid, Year Five Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis] Financial Instrument [Axis] Type of Adoption [Domain] Accounting Standards Update [Domain] Emgality Patent Litigation Emgality Patent Litigation [Member] Emgality Patent Litigation [Member] Net product revenue Product [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Other comprehensive income (loss) from continuing operations: Other Comprehensive Income (Loss), before Tax [Abstract] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] 1.625% Notes due 2026 1.625% Notes Due June 2, 2026 [Member] 1.625% Notes Due June 2, 2026 [Member] Dividends paid Payments of Dividends Operating lease assets Deferred Tax Liabilities, Leasing Arrangements Valuation allowances Deferred Tax Assets, Valuation Allowance Foreign currency exchange rate changes and other adjustments Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Three Actos Actos [Member] Actos Domicile of Litigation [Domain] Domicile Of Litigation [Domain] Domicile Of Litigation Other current liabilities Other Liabilities, Current Net other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Work in process Inventory, Work in Process, Gross Leases [Abstract] Leases [Abstract] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Operating loss carryforwards Operating Loss Carryforwards Earnings per share: Earnings Per Share [Abstract] Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Transitional services agreement, term Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term Amortization of prior service (benefit) cost included in net income Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Investments Valued at Net Asset Value Fair Value Measured at Net Asset Value Per Share [Member] 1.00% Euro denominated notes due 2022 1.0% Euro-denominated Notes Due 2022 [Member] 1.0% Euro-denominated Notes Due 2022 Gain related to disposition of Elanco (Note 19) Gain related to disposition Gain (Loss) on Disposition of Business Disposal Group Name [Domain] Disposal Group Name [Domain] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Fiscal Period Focus Document Fiscal Period Focus Revenue, performance obligation, sales returns, average inventory level (or less) Revenue, Performance Obligation, Sales Returns, Average Inventory Level Revenue, Performance Obligation, Sales Returns, Average Inventory Level Emgality® Emgality [Member] Emgality [Member] Milestone Payments, Development and Regulatory Milestone Payments, Development and Regulatory [Member] Milestone Payments, Development and Regulatory [Member] Employer contribution Defined Benefit Plan, Plan Assets, Contributions by Employer 1.700% Notes due 2049 1.700% Notes due 2049 [Member] 1.700% Notes due 2049 [Member] Changes related to the impact of foreign currency translation, increase Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Entity Filer Category Entity Filer Category Common Stock Common Stock [Member] Product and Service [Domain] Product and Service [Domain] Sales rebates and discounts Sales rebates and discounts Sales rebates and discounts Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Centrexion Therapeutics Corporation Centrexion Therapeutics Corporation [Member] Centrexion Therapeutics Corporation [Member] Dr Reddy's Lab Dr Reddy's Lab [Member] Dr Reddy's Lab [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Schedule of Amounts Recognized in Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Expense under the plans Defined Contribution Plan, Cost Inventories Deferred Tax Liabilities, Inventory Total Derivative Instruments, Gain (Loss) Recognized Derivative Instruments, Gain(loss) Recognized Cialis® Cialis [Member] Cialis [Member] Amounts recognized in the consolidated balance sheet consisted of: Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] Other securities Other Equity Securities [Member] Other Equity Securities [Member] Revenue Benchmark Revenue Benchmark [Member] Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Dividends payable Dividends Payable, Current Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] Common Stock (no par value) Common Class A [Member] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Other—net, (income) expense (Note 18) Other–net, (income) expense Nonoperating Income (Expense) Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Effect from hedged fixed-rate debt Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Foreign Currency Translation Gains (Losses) Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Noncurrent investments: Debt Securities, Available-for-sale [Abstract] Costs, expenses, and other: Costs and Expenses [Abstract] Deferred: Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract] Unrealized Net Gains (Losses) on Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member] Sale of Stock [Domain] Sale of Stock [Domain] State Deferred State and Local Income Tax Expense (Benefit) 2025 Long-Term Debt, Maturity, Year Five Ownership [Domain] Ownership [Domain] Expected return on plan assets for net benefit costs Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Cash payments for interest on borrowings Interest Paid, Excluding Capitalized Interest, Operating Activities Tax Period [Domain] Tax Period [Domain] Maturities on long-term debt Long-term Debt, Fiscal Year Maturity [Abstract] 3.375% notes due 2029 3.375% Notes Due 2029 [Member] 3.375% Notes Due 2029 Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Total equity Beginning balance Ending balance Stockholders' equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Additional paid in capital Additional Paid in Capital Payments for repurchase and redemption of notes payable Proceeds from (Repayments of) Notes Payable Advertising expense, percentage of revenue Advertising Expense, Percentage Of Revenue Advertising Expense, Percentage Of Revenue 2021 Finite-Lived Intangible Asset, Expected Amortization, Year One Revenue Revenue from discontinued operations Revenues Class of Stock [Axis] Class of Stock [Axis] Cash received for sale of antibiotic business in China Proceeds from Divestiture of Businesses AOCI Attributable to Noncontrolling Interest AOCI Attributable to Noncontrolling Interest [Member] Number of patents ruled unpatentable Loss Contingency, Number Of Patents Ruled Unpatentable Loss Contingency, Number Of Patents Ruled Unpatentable Earnings per share - diluted (in usd per share) Earnings Per Share, Diluted Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Schedule of Debt Schedule of Debt [Table Text Block] Forteo® Forteo [Member] Forteo [Member] Goodwill and Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Summary of Long-term Notes Schedule of Long-term Debt Instruments [Table Text Block] Depreciation expense Depreciation Entity Address, Address Line One Entity Address, Address Line One General business credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount Proceeds from divestiture of businesses, net of cash divested Proceeds from Divestiture of Businesses, Net of Cash Divested Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived intangible assets Indefinite-lived Intangible Assets (Excluding Goodwill) Total deferred tax (benefit) expense Deferred Income Tax Expense (Benefit) Roche Roche [Member] Roche [Member] Shares expected to be issued (in shares) Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued The number of shares expected to be issued in the next twelve months under the plan. Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Buy Euro Sell USD Buy Euro Sell Us Dollar [Member] Foreign Currency Forward Commitment to Buy euro Sell US dollar Maximum Maximum [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Noncontrolling Interest Noncontrolling Interest [Member] Net investment gains Gain (Loss) on Investments Purchases of short-term investments Payments to Acquire Short-term Investments Unfunded commitments to invest in venture capital funds Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments Annual net sales threshold (greater than) Collaborative Arrangement, Rights and Obligations, Terms, Annual Net Sales Threshold Collaborative Arrangement, Rights And Obligations, Terms, Annual Net Sales Threshold Change in effective portion of cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Acquisition of common stock in exchange offer (in shares) Stock Acquired During Period, Shares, Exchange Offer Stock Acquired During Period, Shares, Exchange Offer Trading Symbol Trading Symbol Asset Acquisition [Domain] Asset Acquisition [Domain] Asset Acquisition Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Asset impairment, restructuring, and other special charges (Note 5) Total asset impairment, restructuring, and other special charges Restructuring, Settlement and Impairment Provisions Repurchase aggregate principal amount Debt Instrument, Repurchase Amount Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Equipment Equipment [Member] Description of derivative activity volume percent Description of Derivative Activity Volume Percent Label: Description of Derivative Activity Volume Element ID: us-gaap_DescriptionOfDerivativeActivityVolume Balance Type: na Data Type: PERCENT Period Type: duration --------------------------------------------------------------------- Definition: Information that would enable users to understand the volume of the entity's derivative activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 44 -Subparagraph 2 Entity Shell Company Entity Shell Company AbCellera Biologics Inc. (AbCellera) AbCellera Biologics Inc. [Member] AbCellera Biologics Inc. [Member] Zyprexa® Zyprexa [Member] Zyprexa [Member] Entity Public Float Entity Public Float Business Combinations Business Combinations Policy [Policy Text Block] Document Type Document Type ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Other, net (income) expense Other (income) expense Other Nonoperating Income (Expense) Retirement of treasury shares (in shares) Treasury Stock, Shares, Retired Accounts payable and other liabilities—increase (decrease) Increase (Decrease) in Accounts Payable and Accrued Liabilities Common Stock in Treasury Treasury Stock [Member] 1.000% Notes due 2022 1.000% Notes Due June 2, 2022 [Member] 1.000% Notes Due June 2, 2022 [Member] Retirement Benefits Retirement Benefits [Text Block] Milestone Payments, Success-based Regulatory Milestone Payments, Success-based Regulatory [Member] Milestone Payments, Success-based Regulatory Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Acquired IPR&D In Process Research and Development [Member] Cash value of trust owned insurance contract Other Contract [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] 0.45% Swiss Franc denominated notes due 2028 0.45% Swiss Franc Denominated Notes Due 2028 [Member] 0.45% Swiss Franc Denominated Notes Due 2028 Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid 1-5 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five 5.55% notes due 2037 5.55% Notes Due 2037 [Member] 5.55% Notes Due 2037 Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Deferred tax liabilities (Note 14) Deferred Income Tax Liabilities, Net Proceeds from issuance of debt Proceeds from Issuance of Debt Other intangibles, net (Note 8) Carrying Amount, Net Intangible Assets, Net (Excluding Goodwill) Net proceeds from Elanco initial public offering (Note 19) Proceeds from Issuance or Sale of Equity from Subsidiary Proceeds from Issuance or Sale of Equity from Subsidiary Receivables—(increase) decrease Increase (Decrease) in Accounts and Other Receivables Cash flow hedges: Cash Flow Hedge [Abstract] Cash Flow Hedge [Abstract] Severance Severance Costs Schedule of Amounts Recorded for Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Commitments and Contingencies (Note 16) Commitments and Contingencies Noncurrent investments, debt securities Debt Securities, Available-for-sale, Noncurrent Purchases of common stock Payments for Repurchase of Common Stock Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period After Year 5 Lessee, Operating Lease, Liability, to be Paid, after Year Five Income taxes payable (Note 14) Taxes Payable, Current Entity Address, State or Province Entity Address, State or Province Income tax at the U.S. federal statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Accounts payable Accounts Payable, Current Other comprehensive income (loss) from continuing operations before income taxes Other Comprehensive Income (Loss), before Tax Other receivables Derivative Asset, Current Retained earnings Retained Earnings (Accumulated Deficit) Operating lease, right-of-use asset Operating Lease, Right-of-Use Asset Loss on extinguishment of debt Debt extinguishment loss (Note 11) Gain (Loss) on Extinguishment of Debt Unamortized note discounts Debt Instrument, Unamortized Discount 6.77% notes due 2036 6.77% Notes Due 2036 [Member] 6.77% Notes Due 2036 Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Cash payments of income taxes Income Taxes Paid Eli Lilly and Company Shareholders' Equity (Notes 12 and 13) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Derivative liability, notional amount Derivative Liability, Notional Amount Buy USD Sell Euro Buy USD Sell Euro [Member] Buy USD Sell Euro [Member] Merus N.V. Merus N.V. [Member] Merus N.V. Asset impairment (gain) and other special charges Asset Impairment Charges (Recoveries) And Other Special Charges Asset Impairment Charges (Recoveries) And Other Special Charges Customer [Axis] Customer [Axis] Southern District of California Southern District Of California [Member] Southern District Of California Changes related to the impact of foreign currency translation, decrease Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation Income Taxes Income Tax, Policy [Policy Text Block] Hedging Designation [Domain] Hedging Designation [Domain] Earnings from discontinued operations - diluted (in usd per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Equipment Machinery and Equipment, Gross Percentage of nonperforming assets Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets Other investing activities, net Payments for (Proceeds from) Other Investing Activities Sales rebates and discounts Deferred Tax Assets, Sales Rebates And Discounts Deferred Tax Assets, Sales Rebates And Discounts Lessee, lease, remaining lease term (up to) Lessee, Lease, Remaining Lease Term Lessee, Lease, Remaining Lease Term Construction in progress Construction in Progress, Gross Advertising expense Advertising Expense Maturity Date, 2019 Maturity Date, 2019 [Member] Maturity Date, 2019 [Member] Investment Investment, Policy [Policy Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Plaintiff Allegations [Axis] Plaintiff Allegations [Axis] Plaintiff Allegations 3.1% notes due 2027 3.1% Notes Due 2027 [Member] 3.1% Notes Due 2027 Schedule of Research and Development Assets Acquired Other than Through Business Combination Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block] Geographical [Domain] Geographical [Domain] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Other Neuroscience Other Neuroscience [Member] Other Neuroscience [Member] Developed markets Fixed Income Funds [Member] Foreign Deferred Foreign Income Tax Expense (Benefit) Forecast Forecast [Member] Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Entity Voluntary Filers Entity Voluntary Filers Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Number of claimants Loss Contingency, Number Of Claimants Loss Contingency, Number Of Claimants More Than 10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Shares issued (in shares) Preferred Stock, Shares Issued Fochon Pharmaceuticals, Ltd. Fochon Pharmaceuticals, Ltd. [Member] Fochon Pharmaceuticals, Ltd. Land Land U.S. government and agency securities US Government Agencies Debt Securities [Member] Other noncurrent liabilities Derivative Liability, Noncurrent Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Foreign Tax Authority Foreign Tax Authority [Member] 2.5% notes due 2060 2.5% Notes Due 2060 [Member] 2.5% Notes Due 2060 Revenue, performance obligation, sales rebate payment period (up to) Revenue, Performance Obligation, Sales Rebate Payment Period Revenue, Performance Obligation, Sales Rebate Payment Period Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Business Combinations [Abstract] Business Combinations [Abstract] Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Royalty Payments Received Royalty Agreement Terms [Member] Unamortized debt issuance costs Unamortized Debt Issuance Expense Leases Lessee, Finance Leases [Text Block] Research and Development Expense and Acquired In-Process Research and Development (IPR&D) Research and Development Expense, Policy [Policy Text Block] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Fair Value, Assets Measured on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Number of patents Loss Contingency, Number Of Patents Loss Contingency, Number Of Patents Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Entity Central Index Key Entity Central Index Key Debt securities Debt Securities, Available-for-sale, Current Derivative Instrument [Axis] Derivative Instrument [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Finite-lived Intangible Assets other than Goodwill Schedule of Finite-Lived Intangible Assets [Table Text Block] Senior Notes Senior Notes [Member] Geographical [Axis] Geographical [Axis] Share-based Compensation Awards, Fair Value Assumptions Used Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block] Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block] Eddingpharm Eddingpharm [Member] Eddingpharm [Member] Variable rate Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate Retirement benefit plans Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Term Facility Term Facility [Member] Term Facility [Member] Unrealized gross gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] 2024 Long-Term Debt, Maturity, Year Four Three Largest Wholesales Three Largest Wholesales [Member] Three Largest Wholesales [Member] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Outside US And Japan Outside US And Japan [Member] Outside US And Japan Change in defined benefit pension and retiree health benefit plans (Note 15) Total other comprehensive income (loss) during period Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Losses expected to be reclassified in the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Federal Current Federal Tax Expense (Benefit) Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Derivative, notional amount Derivative, Notional Amount Amortization expense Amortization of Intangible Assets Plan amendments during period Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax Sale of Elanco Stock (Note 19) Stock Issued During Period, Value, New Issues Purchases of property and equipment Payments to Acquire Other Property, Plant, and Equipment Scenario [Axis] Scenario [Axis] Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] Other current liabilities Derivative Liability, Current Tax Cuts and Jobs Act, reclassification from AOCI to retained earnings, tax effect Reclassification due to adoption of new accounting standard Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect Equity method investments Equity Method And Other Investments [Member] Equity Method and Other Investments [Member] Title of 12(b) Security Title of 12(b) Security 2018 Repurchase Program 2018 Repurchase Program [Member] 2018 Repurchase Program [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Unrealized losses from equity securities Equity Securities, FV-NI, Gain (Loss) Carrying Amount, Net Finite-Lived Intangible Assets, Net Long-lived assets Long-Lived Assets Weiler v. Takeda Canada Inc. et al. Whyte Et Al. V. Eli Lilly Et Al. [Member] Whyte Et Al. V. Eli Lilly Et Al. Other noncurrent assets Assets for Plan Benefits, Defined Benefit Plan Interest expense Interest Expense Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Acquired IPR&D Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Acquired In-Process Research And Development Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Acquired In-Process Research And Development Other Stockholders' Equity, Other Depreciation and amortization Depreciation, Depletion and Amortization Schedule of Components of Income Tax Expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Discontinued Operations Discontinued Operations [Member] Product and Service [Axis] Product and Service [Axis] Effect from interest rate contracts Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Cross-currency interest rate swaps Cross Currency Interest Rate Contract [Member] Period for recognition of the compensation cost not yet recognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Outside U.S. Non-US [Member] 2022 Long-Term Debt, Maturity, Year Two Acquired in-process research and development (Note 3) Acquired in-process research and development The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT) Other long-term debt Other Notes Payable Defined Benefit Pension and Retiree Health Benefit Plans Amortization of retirement benefit items Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accounting Standards Update 2016-16 Accounting Standards Update 2016-16a [Member] Accounting Standards Update 2016-16a Contract-based intangibles Contract-Based Intangible Assets [Member] Debt Instrument [Axis] Debt Instrument [Axis] Fair value hedges Fair Value Hedging [Member] Schedule of Cash Payments Relating to Income Taxes and Tax Act Toll Tax Schedule of Additional Income Tax Disclosures [Table Text Block] Schedule of Additional Income Tax Disclosures [Table Text Block] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Statement [Line Items] Class of Stock [Line Items] 2.75% notes due 2025 2.75% Notes Due 2025 [Member] 2.75% Notes Due 2025 Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member] Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] Purchase of treasury shares Purchase for treasury Treasury Stock, Value, Acquired, Cost Method Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Litigation Case [Axis] Litigation Case [Axis] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] 2017 Tax Act Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount Operating Activities [Domain] Operating Activities [Domain] Add (deduct): Add (Deduct) [Abstract] Add (Deduct) [Abstract] November 2019 Yen-denominated Notes November 2019 Yen-denominated Notes [Member] November 2019 Yen-denominated Notes Swap Swiss Francs to USD Swap Swiss Francs To U.S. Dollars [Member] Swap Swiss Francs To U.S. Dollars [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Research and development Research and Development Expense Projected benefit obligation Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Subsequent Event Subsequent Event [Member] Collaboration and other revenue associated with prior period transfers of intellectual property Royalty [Member] Erbitux® Erbitux [Member] Erbitux [Member] Foreign currency-denominated notes, designated as hedge Derivatives used in Net Investment Hedge, Net of Tax Fair Value Estimate of Fair Value Measurement [Member] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Four Finite-lived intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax Expiration in 6 Years Expiration in 6 Years [Member] Expiration in 6 Years [Member] Costs, expenses, and other Cost of sales, operating expenses, and other-net Cost of sales, operating expenses, and other-net Current Assets Assets, Current [Abstract] Interest income Investment Income, Interest Domicile of Litigation [Axis] Domicile Of Litigation [Axis] Domicile Of Litigation Remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount International Defined Benefit Plan, Equity Securities, Non-US [Member] Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Change in foreign currency translation gains (losses) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] 2021 Long-Term Debt, Maturity, Year One Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion Rate of compensation increase for benefit obligation Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Legal Entity [Axis] Legal Entity [Axis] City Area Code City Area Code Income Tax Authority [Axis] Income Tax Authority [Axis] Document Period End Date Document Period End Date Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract] Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract] Net investment hedges Net Investment Hedging [Member] Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Curtailment gain (loss) Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax Net income Total reclassifications for the period, net of tax Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Net amount reclassified from accumulated other comprehensive loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Net change in short-term borrowings Proceeds from (Repayments of) Short-term Debt Other Other Product, Total [Member] Other Product, Total [Member] Other financing activities, net Proceeds from (Payments for) Other Financing Activities 4.65% notes due 2044 4.65% Notes Due 2044 [Member] 4.65% Notes Due 2044 Intangible Assets, Net (Excluding Goodwill) [Abstract] Intangible Assets, Net (Excluding Goodwill) [Abstract] Cover [Abstract] Cover [Abstract] 2.25% notes due 2050 2.25% Notes Due 2050 [Member] 2.25% Notes Due 2050 [Member] Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Current: Current Federal, State and Local, Tax Expense (Benefit) [Abstract] Maximum remaining maturity of foreign currency derivatives Maximum Remaining Maturity of Foreign Currency Derivatives Deconsolidation of Elanco Impact on Equity of Sale of Noncontrolling Interest in Subsidiary Impact on Equity of Sale of Noncontrolling Interest in Subsidiary Total long-term notes Long-term debt, including current portion Total long-term notes Long-term Debt Leases Lessee, Operating Leases [Text Block] Service cost Service cost Defined Benefit Plan, Service Cost Other-Net, (Income) Expense Other Income and Other Expense Disclosure [Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Cost of sales Cost of Goods and Services Sold Equity Components [Axis] Equity Components [Axis] Number of lawsuits Loss Contingency, Pending Claims, Number Humalog, Humulin and Forteo Humalog, Humulin, And Forteo [Member] Humalog, Humulin, And Forteo Percentage of global investments in plan assets Defined Benefit Plan, Percentage of Global Investments in Plan Assets Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance Number of requests for information Loss Contingency, Number Of Requests For Information Loss Contingency, Number Of Requests For Information Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Total gross deferred tax assets Deferred Tax Assets, Gross Minimum Minimum [Member] Cyramza® Cyramza [Member] Cyramza [Member] 2.125% Notes due 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] Milestone Payments, Sales-based Milestone Payments, Sales-based [Member] Milestone Payments, Sales-based [Member] 1.7% Euro denominated notes due 2049 1.7% Euro-deonominated Notes Due 2049 [Member] 1.7% Euro-deonominated Notes Due 2049 [Member] Long-term debt assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Accumulated benefit obligation Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Europe Europe [Member] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Marketable equity securities Defined Benefit Plan, Equity Securities [Member] Other Other Product [Member] Other Product [Member] Operating lease liabilities Deferred Tax Assets, Operating Lease, Liability Deferred Tax Assets, Operating Lease, Liability Fair Value, Liabilities Measured on Recurring Basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Recognized actuarial loss (gain) Defined Benefit Plan, Amortization of Gain (Loss) Asset-backed securities Asset-backed Securities [Member] Schedule of Amounts Recognized in Balance Sheet Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Net periodic (benefit) cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) U.S. UNITED STATES Schedule of Allocation of Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] SIGA Technologies, Inc. SIGA Technologies [Member] SIGA Technologies [Member] Share-based Compensation, Option and Incentive Plans Share-based Payment Arrangement [Policy Text Block] Foreign Current Foreign Tax Expense (Benefit) Actuarial losses Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Derivative [Table] Derivative [Table] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Real estate Defined Benefit Plan, Real Estate [Member] 2021 Defined Benefit Plan, Expected Future Benefit Payment, Year One Total deferred tax liabilities Deferred Tax Liabilities, Gross Long-term income taxes payable, estimated timing of future cash outflows not possible Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible Advertising Expenses Advertising Cost [Policy Text Block] Payments for income tax settlements Payments For Income Tax Settlements Payments For Income Tax Settlements Carrying Amount, Gross Intangible Assets, Gross (Excluding Goodwill) Retirement Plan Type [Domain] Retirement Plan Type [Domain] Contingent value right, additional price per share (in dollars per share) Business Acquisition, Contingent Value Right, Additional Price Per Share Business Acquisition, Contingent Value Right, Additional Price Per Share Decrease in unrecognized tax benefits is reasonably possible Decrease in Unrecognized Tax Benefits is Reasonably Possible Asset Impairment, Restructuring, And Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] 3.95% notes due 2047 3.95% Notes Due 2047 [Member] 3.95% Notes Due 2047 Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Actuarial gain (loss) arising during period Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Purchases of noncurrent investments Payments to Acquire Other Investments Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Goodwill, impairment loss Goodwill, Impairment Loss Accounts receivable, net of allowances of $25.9 (2020) and $22.4 (2019) Accounts Receivable, after Allowance for Credit Loss, Current Finished products Inventory, Finished Goods, Gross Total lease payments Lessee, Operating Lease, Liability, to be Paid Disposition of ownership interest Noncontrolling Interest, Ownership Percentage by Parent Other Deferred Tax Assets, Other Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Cymbalta® Cymbalta [Member] Cymbalta [Member] Emerging markets Fixed Income Funds Emerging Markets [Member] An investment that pools funds from many investors to invest in a combination of underlying investments, primarily fixed income investments in EMERGING MARKETS. Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Less Than 1 Year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Document Transition Report Document Transition Report Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Nonoperating Income (Expense) [Abstract] Nonoperating Income (Expense) [Abstract] Change in net unrealized gains (losses) on securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax Prepaid employee benefits Deferred Tax Liabilities, Prepaid Expenses Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Consideration received Disposal Group, Including Discontinued Operation, Consideration Hydra Biosciences Hydra Biosciences [Member] Hydra Biosciences [Member] Components of net periodic (benefit) cost: Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Retiree Health Benefit Plans Postretirement Health Coverage [Member] Derivative asset, notional amount Derivative Asset, Notional Amount Earnings from discontinued operations - basic (in usd per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Expiration in 12 to 18 Years Expiration In 12 To 18 Years [Member] Expiration In 12 To 18 Years [Member] Litigation Case Type [Domain] Litigation Case [Domain] Earnings per share - basic (in usd per share) Earnings Per Share, Basic Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Entity File Number Entity File Number Curtailment gain Curtailment (gain) loss Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Accrued retirement benefits (Note 15) Accrued retirement benefits Liability, Defined Benefit Plan, Noncurrent Rate of compensation increase for net benefit costs Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Net amount recognized Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Net income from discontinued operations (Note 19) Reclassifications from discontinued operations (net of tax) Net income from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Summary of Revenue and Net Income from Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Unrecognized prior service (benefit) cost Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Stock-based compensation expense Share-based Payment Arrangement, Expense Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Number of plaintiffs Loss Contingency, Number of Plaintiffs Issuance of stock under employee stock plans, net Stock Issued During Period, Value, Employee Stock Purchase Plan Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Disposal Group Name [Axis] Disposal Group Name [Axis] Document Annual Report Document Annual Report Other Immunology Other Immunology [Member] Other Immunology Commercial Paper Commercial Paper [Member] Tax benefit Share-based Payment Arrangement, Expense, Tax Benefit Senior Notes Due May 2050 and September 2060 Senior Notes Due May 2050 And September 2060 [Member] Senior Notes Due May 2050 And September 2060 Retirement Benefits [Abstract] Retirement Benefits [Abstract] Number of patents, claims dismissed Loss Contingency, Number Of Patents, Claims Dismissed Loss Contingency, Number Of Patents, Claims Dismissed Summary of Income Tax Contingencies Summary of Income Tax Contingencies [Table Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Los Angeles Los Angeles [Member] Los Angeles Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Employee benefit trust Employee benefit trust Common Stock, Shares Held in Employee Trust Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Mortgage-backed securities Collateralized Mortgage Backed Securities [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] 5.5% notes due 2027 5.5% Notes Due 2027 [Member] 5.5% Notes Due 2027 Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Rent expense Operating Leases, Rent Expense, Net Foreign Currency Denominated Debt Foreign Currency Denominated Debt [Member] Foreign Currency Denominated Debt [Member] Total liabilities and equity Liabilities and Equity Buildings Buildings and Improvements, Gross Loss Contingencies [Line Items] Loss Contingencies [Line Items] Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Accumulated other comprehensive loss (Note 17) Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Income Taxes Income Tax Disclosure [Text Block] Total other liabilities Liabilities, Noncurrent Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Lapses of statutes of limitation Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Lease expense Operating Lease, Cost Total consideration transferred - net of cash acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Hedging Relationship [Axis] Hedging Relationship [Axis] Total current tax expense Current Income Tax Expense (Benefit) Additions for tax positions of prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Additions based on tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Equity Component [Domain] Equity Component [Domain] Other noncurrent assets Derivative Asset, Noncurrent Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Property and equipment, net (Note 9) Property and equipment, net Property, Plant and Equipment, Net Foreign tax redeterminations Deferred Tax Assets, Foreign Tax Redeterminations Deferred Tax Assets, Foreign Tax Redeterminations Entity Tax Identification Number Entity Tax Identification Number Foreign currency exchange rate changes and other adjustments Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Hedge funds Hedge Funds [Member] Stock-Based Compensation Share-based Payment Arrangement [Text Block] Interest Rate Contract Interest Rate Contract [Member] Net income Net income Net Income (Loss) Attributable to Parent Other changes in operating assets and liabilities, net of acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] Inventories Inventory Disclosure [Text Block] Dicerna Pharmaceuticals Inc. Dicerna Pharmaceuticals [Member] Dicerna Pharmaceuticals [Member] Current Fiscal Year End Date Current Fiscal Year End Date Tyvyt TYVYT [Member] TYVYT Number of legacy antibiotic medicines rights sold Number Of Medicines, Rights To, Sold Number Of Medicines, Rights To, Sold Current federal tax expense, utilization of net operating loss carryforward Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward Pancreatic Cancer or Thyroid Cancer Pancreatic Cancer Or Thyroid Cancer [Member] Pancreatic Cancer Or Thyroid Cancer Correlative tax adjustments Deferred Tax Assets, Corrective Tax Adjustments Deferred Tax Assets, Corrective Tax Adjustments Intangibles acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Marketed products Developed Technology Rights [Member] Tax credit carryforwards and carrybacks Deferred Tax Assets, Tax Credit Carryforwards Proceeds from sales and maturities of short-term investments Proceeds from Sale of Short-term Investments Oncology Oncology [Member] Revenue to unaffiliated customers, Oncology Milestone Payments, Success-based Regulatory And Sales-based Milestone Payments, Success-based Regulatory And Sales-based [Member] Milestone Payments, Success-based Regulatory And Sales-based Shareholder Value Awards Shareholder Value Awards [Member] Shareholder Value Awards are granted to officers and management and are payable in shares of common stock at the end of a 3 yr period. Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Tax Cut And Jobs Act, Toll Tax, Payment, Due [Abstract] Tax Cut And Jobs Act, Toll Tax, Payment, Due [Abstract] Tax Cut And Jobs Act, Toll Tax, Payment, Due Issuance of stock under employee stock plans, net (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans U.S. Defined Benefit Plan, Equity Securities, US [Member] Undisclosed Undisclosed Asset Acquisition [Member] Undisclosed Asset Acquisition Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] 6.77% Notes due 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Financial instruments Deferred Tax Liabilities, Derivatives Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Line of credit facility, remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items Other Comprehensive Income (Loss), Tax Carrying Amount, Gross Finite-Lived Intangible Assets, Gross Accumulated other comprehensive (income) loss before income taxes Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax Other, net of tax Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Average remaining maturity of foreign currency derivatives Average Remaining Maturity of Foreign Currency Derivatives Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Unrecognized net actuarial (gain) loss Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract] Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract] Relative Value Awards Relative Value Awards [Member] Relative Value Awards Collaboration and other revenue Collaboration and Other Revenue [Member] Collaboration and Other Revenue [Member] Hedging Relationship [Domain] Hedging Relationship [Domain] Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Ownership [Axis] Ownership [Axis] Document Information [Line Items] Document Information [Line Items] Precision BioSciences, Inc. Precision BioSciences, Inc. [Member] Precision BioSciences, Inc. Cash flow hedges Cash Flow Hedging [Member] Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Company [Member] Chugai Pharmaceutical Company [Member] Loss Contingencies [Table] Loss Contingencies [Table] Carrying Amount Reported Value Measurement [Member] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Revenue Revenue from Contract with Customer [Text Block] Less than 1 Year Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Actuarial loss Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Prevail Therapeutics Inc. Prevail Therapeutics Inc. [Member] Prevail Therapeutics Inc. Humulin® Humulin [Member] Humulin [Member] Inventories Inventory, Policy [Policy Text Block] Income taxes (Note 14) Income taxes Income taxes Income Tax Expense (Benefit) Jardiance® Jardiance Jardiance [Member] Jardiance [Member] Humalog® Humalog [Member] Humalog [Member] Plaintiff Allegations [Domain] Plaintiff Allegations [Domain] Plaintiff Allegations Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-term Debt [Table Text Block] Consideration transferred, equity interests purchased Payments to Acquire Marketable Securities Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] NextCure, Inc. NextCure, Inc. [Member] NextCure, Inc. [Member] Local Phone Number Local Phone Number Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract] Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract] Disarm Therapeutics, Inc. (Disarm) Disarm Therapeutics, Inc. [Member] Disarm Therapeutics, Inc. Payments for acquisitions Payments to Acquire Businesses, Gross Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Finite-lived Intangible Assets Amortization Expense Finite-lived Intangible Assets Amortization Expense [Table Text Block] Revenue Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Derivative [Line Items] Derivative [Line Items] Schedule of Indefinite-lived Intangible Assets other than Goodwill Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Prior service benefits, net Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member] Long-term notes, gross Long-term Debt, Gross Reductions for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Trajenta® Trajenta (BI) [Member] Trajenta (BI) [Member] Contract liabilities Contract liabilities Contract with Customer, Liability Other assets—(increase) decrease Increase (Decrease) in Other Operating Assets Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Contingent value right, additional price per share, aggregate amount Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Internal Revenue Service (IRS) Internal Revenue Service (IRS) [Member] Award Type [Axis] Award Type [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Discount rate for net benefit costs Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Short-term commercial paper borrowings Short-term commercial paper borrowings Commercial Paper Buy USD Sell Japanese Yen Buy US dollar Sell Japanese Yen [Member] Buy US dollar Sell Japanese Yen [Member] Other Define Benefit Plan, Other [Member] Define Benefit Plan, Other [Member] Retained Earnings Retained Earnings [Member] Measurement Basis [Axis] Measurement Basis [Axis] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Schedule of Net Benefit Costs Schedule of Net Benefit Costs [Table Text Block] Net Cash Provided by (Used for) Investing Activities Net Cash Provided by (Used in) Investing Activities Award Type [Domain] Award Type [Domain] Other current liabilities Liability, Defined Benefit Plan, Current Other Liabilities Liabilities, Noncurrent [Abstract] Developed markets - repurchase agreements Fixed Income Funds - Repurchased Agreements [Member] Fixed Income Funds - Repurchased Agreements [Member] Corporate debt securities Corporate Debt Securities [Member] Capitalized research and development Deferred Tax Assets, in Process Research and Development Cash distributed to Elanco upon disposition Cash Divested from Deconsolidation Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] 0.56% Japanese Yen denominated notes due 2034 .56% Yen-denominated Notes Due 2034 [Member] .56% Yen-denominated Notes Due 2034 [Member] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Continuing Operations Continuing Operations [Member] Cost of common stock in treasury Treasury Stock, Value Defined Benefit Pension Plans Pension Plan [Member] Discount rate for benefit obligation Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Current Liabilities Liabilities, Current [Abstract] Implementation of New Financial Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Short-term investments (Note 7) Short-term Investments